EUVIMEDEUVIMED entdecken
Open Access

TP53/KRAS variant allele frequency ratio predicts advanced disease in mucin-producing cystic neoplasms of the pancreas

Ming-Tseh Lin, Elham Afghani, Marcia I Canto, Jing Zhu, Syed Z Ali, Laura D Wood, Jin He iD, Kelly J Lafaro iD, Ralph H Hruban, James R Eshleman

Am J Clin Pathol · 2026

DOI: 10.1093/ajcp/aqaf133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Am J Clin Pathol, 2026. Verfasst von Ming-Tseh Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, United…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras). Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To identify molecular markers that predict advanced disease in mucin-producing cystic neoplasms of the pancreas.

Methods

In this single-institution study, 454 pancreatic cystic fluid specimens were examined by a clinical next-generation sequencing assay.

Results

TP53 mutations were detected in 25 (7.9%) of 318 specimens harboring KRAS (BRAF or GNAS) mutation(s). Of the 25, 12 had advanced cytology/histology (positive group), and 5 did not have advanced cytology/histology (negative group). Eight cases were classified as indeterminate. Since KRAS and TP53 variant allele frequencies (VAFs) can be as low as 1% to 5%, we analyzed the TP53/KRAS VAF ratio and demonstrated a significantly higher VAF ratio in the positive group (P = .005). A VAF ratio of 1 or higher, interpreted as an indicator of a dominant TP53 clone, and concurrent TP53, CDKN2A, and SMAD4 mutations were seen only in the positive group. Lower TP53 ratios, interpreted as a minor TP53 clone, were seen in all 5 negative group specimens.

Conclusions

These results suggest that VAF ratios and concurrent mutations can be incorporated into multimodality assessments of pancreatic cysts. Longitudinal studies in patients with a lower initial TP53 VAF ratio are warranted to elucidate whether serial VAF ratios are more accurate markers than a single VAF measurement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsTumor Suppressor Protein p53Proto-Oncogene Proteins p21(ras)HumansMaleFemaleMiddle AgedMutationAdultAgedGene FrequencyBiomarkers, TumorMucinsAged, 80 and overPancreatic Cyst

Stichwörter der Autor:innen

KRASTP53IPMNVAF ratioadvanced neoplasmspancreas

Substanzen

Tumor Suppressor Protein p53Proto-Oncogene Proteins p21(ras)KRAS protein, humanTP53 protein, humanBiomarkers, TumorMucins

Autor:innen und Institutionen

  • Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, United States.
  • Department of Gastroenterology & Hepatology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, United States.
  • Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, United States.
  • Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, United States.

ORCID-Profile: Jin He, Kelly J Lafaro

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Lin, M. T., Afghani, E., Canto, M. I., Zhu, J., Ali, S. Z., Wood, L. D., He, J., Lafaro, K. J., Hruban, R. H., & Eshleman, J. R. (2026). TP53/KRAS variant allele frequency ratio predicts advanced disease in mucin-producing cystic neoplasms of the pancreas. Am J Clin Pathol. https://doi.org/10.1093/ajcp/aqaf133

Vancouver

Lin MT, Afghani E, Canto MI, Zhu J, Ali SZ, Wood LD, et al. TP53/KRAS variant allele frequency ratio predicts advanced disease in mucin-producing cystic neoplasms of the pancreas. Am J Clin Pathol. 2026. doi:10.1093/ajcp/aqaf133

BibTeX
@article{Lin2026,
  author = {Lin, Ming-Tseh and Afghani, Elham and Canto, Marcia I and Zhu, Jing and Ali, Syed Z and Wood, Laura D and He, Jin and Lafaro, Kelly J and Hruban, Ralph H and Eshleman, James R},
  title = {TP53/KRAS variant allele frequency ratio predicts advanced disease in mucin-producing cystic neoplasms of the pancreas},
  journal = {Am J Clin Pathol},
  year = {2026},
  doi = {10.1093/ajcp/aqaf133}
}
Kostenlos starten →